Feb 27, 2017
9:30 AM–10:30 AM (EST)
Duration: 1hrs

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses. Early detection of breast cancer metastasis would allow for changes in treatment strategy before the disease progression becomes apparent. In this webinar, we will demonstrate the enrichment and detection value – as well as the prognostic and predictive value – of the AdnaTestBreast in breast cancer.


Using the Combination of Combinations Principle (COCP), AdnaTest BreastCancer enables highly specific immunomagnetic cell selection for enriching circulating tumor cells (CTCs) from peripheral blood. It also allows sensitive analysis of breast cancer-associated gene expression in enriched CTCs by reverse transcription and PCR. The high performance of AdnaTest BreastCancer has been demonstrated in dozens of peer-reviewed publications. Several studies have reported that HER2 expression is different in primary tumors compared to CTCs. In addition, AdnaTestBreast HER2 overexpression profile corresponds to HER2 metastatic phenotype; and HER2 detected by the AdnaTestBreast and AdnaTest EMT-2/StemCell seems to initiate EMT and tumor stemness.

Back to top